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Many investigators have tried to establish the
prevalence of neuropathic pain in the general
population; however, the estimates vary greatly
(from 0.9% to 17.9%) [1] according to the
method used. In particular, the estimates are
low when neurological diseases that cause pain
are assessed, and high when typical neuropathic
pain symptoms are considered. Surveys con-
ducted in the European general population
reported that the prevalence of neuropathic
pain was 7% [2], while 4% of responders had
chronic pain secondary to nerve disease and
10% were being treated by neurologists or
neurosurgeons [3]. We believe that the 2012
analytic review by Smith and Torrance [4]—
which also includes data from the US—provides
the most realistic estimate: 6–8%, a proportion
that is likely to increase in the future [5].
Neuropathic pain is a chronic condition and
represents a significant burden for patients and
healthcare systems. The quality of life is worse
in patients with neuropathic pain than in those
with other types of chronic pain [4]. Although
the costs to healthcare systems are difficult to
calculate, as they are fragmented based on the
underlying disease, the overall expenditure on
neuropathic pain is likely very high. Further-
more, neuropathic pain leads to psychosocial
and emotional disorders that increase the bur-
den on society [6].
The magnitude of the problem has been
understood by both investigators and the
pharmaceutical industry. A search of the
PubMed database for the string ‘‘neuropathic
pain’’ in the field Title/Abstract yielded 1020
articles published from inception to 1999 and
14,727 articles from 2000 to August 2017. Even
more importantly, the number of clinical trials
of drugs for the treatment of neuropathic pain
increased from 104 to 892, indicating that a
great amount of effort has been devoted to
dealing with this problem.
Despite this attention, management of neu-
ropathic pain continues to be a challenge [7].
Indeed, less than 50% of patients achieve pain
relief of at least 50% with any drug or combi-
nation of drugs, whether old or new [8]. The
current estimates, in fact, are well below that
number [9]. Why is this so? Although the pos-
sible answers are many, the explanation that we
favor most is that there are multiple patho-
physiological mechanisms of neuropathic pain,
whereas most drugs have a mechanism of action
that addresses only one pain mechanism. One
patient may often suffer from different types of
neuropathic pain, and no one drug can effec-
tively relieve all types of pain.
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This view has prompted investigators to try,
through a careful assessment of the so-called
sensory profiles, to identify the underlying pain
mechanisms, and thus provide a more targeted
treatment [7, 9, 10]. The need for this implies
that the standard guidelines on neuropathic
pain treatment, which are based on clinical tri-
als that assess drug efficacy in patients who are
enrolled because they are affected by a particu-
lar disease rather than a type of pain, necessarily
fail to adequately address the problem.
Another research direction that holds sig-
nificant promise in the field of neuropathic pain
treatment is the use of combination therapies.
By addressing different pathophysiological
mechanisms, combination therapies can help
patients achieve better pain relief than that
provided by single-drug therapies [11]. Already
widely used in routine practice, some combi-
nation therapies have now been included in
clinical practice guidelines [12].
In this special issue of Pain and Therapy, a
group of authors from the Neuropathic Pain
Special Interest Group of the Italian Society of
Neurology (Italian NeuPSIG) consider the
problems associated with neuropathic pain,
including pathophysiological mechanisms and
pharmacology, the limitations of guidelines in
clinical practice, and the apparently inescapable
vicious circle of neuropathic pain and emo-
tional and sleep disorders, where one disorder
seems to reinforce the other.
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